[
    [
        {
            "time": "2023-10-01",
            "original_text": "药明康德是如何\"逆袭\"的？",
            "features": {
                "keywords": [
                    "药明康德",
                    "逆袭"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "News_content": "药明康德是如何\"逆袭\"的？",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 6,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 8,
                "Market_Scope": 4,
                "Time_Proximity": 5,
                "Headline_Structure": 8,
                "Source_Recency": 6
            }
        },
        {
            "time": "2023-10-01",
            "original_text": "睿智医药乱象丛生 盈利能力低下 增速远逊同行",
            "features": {
                "keywords": [
                    "睿智医药",
                    "乱象",
                    "盈利能力",
                    "增速"
                ],
                "sentiment_score": -0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "睿智医药乱象丛生 盈利能力低下 增速远逊同行",
                "Correlation": 7,
                "Sentiment": 2,
                "Importance": 6,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 7,
                "Market_Scope": 3,
                "Time_Proximity": 5,
                "Headline_Structure": 9,
                "Source_Recency": 6
            }
        },
        {
            "time": "2023-10-01",
            "original_text": "CRO淘金赛道“领跌者” 泰格医药转型“投资家”AB面",
            "features": {
                "keywords": [
                    "CRO",
                    "泰格医药",
                    "领跌",
                    "转型",
                    "投资家"
                ],
                "sentiment_score": -0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "CRO淘金赛道“领跌者” 泰格医药转型“投资家”AB面",
                "Correlation": 8,
                "Sentiment": 5,
                "Importance": 7,
                "Impact": 6,
                "Duration": 6,
                "Entity_Density": 6,
                "Market_Scope": 7,
                "Time_Proximity": 5,
                "Headline_Structure": 8,
                "Source_Recency": 6
            }
        },
        {
            "time": "2023-10-01",
            "original_text": "2021年医药生物中期策略报告：需求长期景气 布局创新、医疗服务和消费主线",
            "features": {
                "keywords": [
                    "医药生物",
                    "需求",
                    "景气",
                    "创新",
                    "医疗服务",
                    "消费"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "News_content": "2021年医药生物中期策略报告：需求长期景气 布局创新、医疗服务和消费主线",
                "Correlation": 5,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 5,
                "Duration": 8,
                "Entity_Density": 3,
                "Market_Scope": 9,
                "Time_Proximity": 4,
                "Headline_Structure": 6,
                "Source_Recency": 4
            }
        },
        {
            "time": "2023-10-01",
            "original_text": "豪掷98亿！泰格医药大手笔设产业基金",
            "features": {
                "keywords": [
                    "泰格医药",
                    "产业基金",
                    "投资"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "News_content": "豪掷98亿！泰格医药大手笔设产业基金",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 6,
                "Headline_Structure": 9,
                "Source_Recency": 7
            }
        },
        {
            "time": "2023-10-01",
            "original_text": "人类基因组编辑要如何监管？世卫组织今日发布最新推荐",
            "features": {
                "keywords": [
                    "人类基因组",
                    "编辑",
                    "监管",
                    "世卫组织"
                ],
                "sentiment_score": 0.5,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "生物科技"
                ],
                "causal_factor": "true",
                "causal_impact": "neutral",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "News_content": "人类基因组编辑要如何监管？世卫组织今日发布最新推荐",
                "Correlation": 4,
                "Sentiment": 5,
                "Importance": 6,
                "Impact": 4,
                "Duration": 5,
                "Entity_Density": 2,
                "Market_Scope": 8,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "2023-10-01",
            "original_text": "CRISPR基因编辑敲除PD-1，“改良版”即用型CAR-T疗法进入临床试验",
            "features": {
                "keywords": [
                    "CRISPR",
                    "基因编辑",
                    "PD-1",
                    "CAR-T",
                    "临床试验"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "生物科技"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "News_content": "CRISPR基因编辑敲除PD-1，“改良版”即用型CAR-T疗法进入临床试验",
                "Correlation": 6,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 6,
                "Duration": 7,
                "Entity_Density": 4,
                "Market_Scope": 8,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "2023-10-01",
            "original_text": "降低疾病进展风险37%，杨森CD38抗体组合获批二线治疗多发性骨髓瘤",
            "features": {
                "keywords": [
                    "杨森",
                    "CD38",
                    "抗体",
                    "多发性骨髓瘤"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "News_content": "降低疾病进展风险37%，杨森CD38抗体组合获批二线治疗多发性骨髓瘤",
                "Correlation": 5,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 5,
                "Duration": 7,
                "Entity_Density": 3,
                "Market_Scope": 7,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        },
        {
            "time": "2023-10-01",
            "original_text": "药明康德：因零息可转换债券获转换，发行139.88万股",
            "features": {
                "keywords": [
                    "药明康德",
                    "可转换债券",
                    "发行"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "药明康德：因零息可转换债券获转换，发行139.88万股",
                "Correlation": 10,
                "Sentiment": 5,
                "Importance": 7,
                "Impact": 6,
                "Duration": 4,
                "Entity_Density": 10,
                "Market_Scope": 2,
                "Time_Proximity": 8,
                "Headline_Structure": 6,
                "Source_Recency": 9
            }
        },
        {
            "time": "2023-10-01",
            "original_text": "因零息可转换债券获转换 药明康德(02359)发行139.88万股A股",
            "features": {
                "keywords": [
                    "药明康德",
                    "可转换债券",
                    "发行"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "因零息可转换债券获转换 药明康德(02359)发行139.88万股A股",
                "Correlation": 10,
                "Sentiment": 5,
                "Importance": 7,
                "Impact": 6,
                "Duration": 4,
                "Entity_Density": 10,
                "Market_Scope": 2,
                "Time_Proximity": 8,
                "Headline_Structure": 6,
                "Source_Recency": 9
            }
        },
        {
            "time": "2023-10-01",
            "original_text": "药明康德：因期权获行使，发行13.405万股A股",
            "features": {
                "keywords": [
                    "药明康德",
                    "期权",
                    "发行"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "药明康德：因期权获行使，发行13.405万股A股",
                "Correlation": 10,
                "Sentiment": 5,
                "Importance": 6,
                "Impact": 5,
                "Duration": 4,
                "Entity_Density": 10,
                "Market_Scope": 2,
                "Time_Proximity": 8,
                "Headline_Structure": 6,
                "Source_Recency": 9
            }
        },
        {
            "time": "2023-10-01",
            "original_text": "因期权获行使 药明康德(02359)发行13.405万股A股",
            "features": {
                "keywords": [
                    "药明康德",
                    "期权",
                    "发行"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "因期权获行使 药明康德(02359)发行13.405万股A股",
                "Correlation": 10,
                "Sentiment": 5,
                "Importance": 6,
                "Impact": 5,
                "Duration": 4,
                "Entity_Density": 10,
                "Market_Scope": 2,
                "Time_Proximity": 8,
                "Headline_Structure": 6,
                "Source_Recency": 9
            }
        }
    ]
]